All News
Filter News
Found 421 articles
-
Affimed Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform
1/11/2017
-
Avacta Group Demonstrates Key Performance Benefits Of Affimer Technology For Affinity Separation
11/23/2016
-
Avacta Group Release: Positive Results From First Preclinical In-Vivo Studies Of Affimer Therapeutics
9/22/2016
-
Affimed To Present At Upcoming Investor Conferences
9/1/2016
-
Affimed Announces Annual General Meeting Of Shareholders
5/24/2016
-
Affimed To Present At The UBS Global Healthcare Conference -- New York
5/17/2016
-
Affimed Presents Data On AFM13-Mediated Innate/Adaptive Immune Crosstalk At The AACR Annual Meeting 2016
4/21/2016
-
Affimed Presents Data On EGFRwt and EGFRvIII-Targeting NK- And T-Cell Tandabs At The AACR Annual Meeting 2016
4/21/2016
-
Avacta Group Release: Affimer Therapeutic Platform Development Milestone Achieved
4/19/2016
-
Kiadis Pharma Proposes Robert Soiffer And Berndt Modig As Its New Supervisory Board Members
4/7/2016
-
Affimed Reports Financial Results For Fourth Quarter And Year End 2015
3/30/2016
-
Affimed Announces Fourth Quarter And Year End 2015 Financial Results And Corporate Update Conference Call
3/23/2016
-
Affimed To Present Data On NK- And T-Cell Engagers At The AACR Annual Meeting 2016
3/17/2016
-
Affimed To Present At The Cowen and Company 36th Annual Health Care Conference
2/29/2016
-
Avacta Group Awarded Grant Funding
2/24/2016
-
Affimed To Speak At Symposium On Emerging Approaches In Cancer Immunotherapy
2/22/2016
-
Affimed To Present At The Leerink Partners 5th Annual Global Healthcare Conference
2/4/2016
-
Affimed Therapeutics AG Enters Into Collaboration With Merck & Co. To Evaluate AFM13 In Combination With KEYTRUDA (Pembrolizumab) For Patients With Hodgkin Lymphoma
1/25/2016
-
Avacta Group plc Pre-Close Trading Update
1/25/2016
-
Avacta Group plc Appoints Philippe Cotrel As Chief Commercial Officer
1/25/2016